<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975754</url>
  </required_header>
  <id_info>
    <org_study_id>D5252M00001</org_study_id>
    <nct_id>NCT00975754</nct_id>
  </id_info>
  <brief_title>Lung Deposition Via Different Inhalation Devices</brief_title>
  <official_title>A Phase I, Randomized, Open-label, 5-way Crossover, Single Centre Study in Healthy Subjects to Assess the Lung Deposition of Inhaled Budesonide Delivered Via Different Inhalation Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the deposition of budesonide to the lung after
      inhalation with 5 different devices and to relate the findings to in vitro properties of
      inhaled budesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung deposition of budesonide (AUC)</measure>
    <time_frame>Before dose and repeatadly during the 8-hour period after dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide pMDI + Aerochamber Zero-stat spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort repulses via Spira Nebuliser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort Turbohaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort pMDI HFA</intervention_name>
    <description>Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide pMDI HFA</intervention_name>
    <description>Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort Repulses</intervention_name>
    <description>Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort Turbohaler</intervention_name>
    <description>Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  BMI between 18 and 30 kg/m2

          -  Non-smokers/non-snuffers

        Exclusion Criteria:

          -  Pregnant and/or lactating women

          -  Use of oral contraceptives or hormonal implants

          -  Known or suspected hypersensitivity to glucocorticosteroids, inhaled lactose, or other
             excipients in study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pia Lena Berg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit, AstraZeneca R&amp;D Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>December 10, 2009</last_update_submitted>
  <last_update_submitted_qc>December 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD Carin Jorup, MD, Emerging respiratory</name_title>
    <organization>AstraZeneca R&amp;D Lund</organization>
  </responsible_party>
  <keyword>Inhalation</keyword>
  <keyword>lung deposition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

